A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

October 17, 2022

Study Completion Date

November 11, 2022

Conditions

Myopic Choroidal Neovascularization

Interventions

DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

As prescribed by the treating physician

Trial Locations (1)

Many Locations, Multiple Locations